Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)

Christian E. Antoni, Arthur Kavanaugh, Désirée Van Der Heijde, Anna Beutler, Gregory Keenan, Bei Zhou, Bruce Kirkham, Zuhre Tutuncu, Gerd R. Burmester, Udo Schneider, Daniel E. Fürst, Jerry Molitor, Edward Keystone, Dafna D. Gladman, Bernhard Manger, Siegfried Wassenberg, Ralf Weier, Daniel J. Wallace, Michael H. Weisman, Joachim R. KaldenJosef S. Smolen

Research output: Contribution to journal › Article › peer-review

146 Scopus citations

Fingerprint

Dive into the research topics of 'Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)'. Together they form a unique fingerprint.

Medicine & Life Sciences